Study Of Palbociclib (PD-0332991) In Renal Impairment
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Since the amount of palbociclib eliminated in urine is 6.9%, renal impairment is not expected
to have much impact on palbociclib. However, the Federal Drug Administration (FDA) Guidance
recommends a study in subjects with renal impairment when the drug is likely to be used in
patients with impaired renal function. Palbociclib is intended for chronic use in cancer
patients who may have some degree of impaired renal function.